**Supplementary Table S3. Clinicopathological features in patients with NSCLC (n = 27).**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Characteristics** |  | **PD-L1** | | ***P*** |  | **PD-L2** | | ***P*** |
|  | **(-)**  **(n = 12)** | **(+)**  **(n = 15)** |  | **(-)**  **(n = 4)** | **(+)**  **(n = 23)** |
| **Age (average)** |  | 71.6 | 71.5 | 0.96 |  | 73.3 | 71.2 | 0.50 |
| **Sex**  Male/female |  | 12/0 | 14/1 | 1.00 |  | 4/0 | 22/1 | 1.00 |
| **Smoking status**  Current or former/never |  | 11/1 | 13/2 | 1.00 |  | 4/0 | 20/3 | 0.39 |
| **Driver gene**  *EGFR*/*ALK*/wild-type |  | 0/0/12 | 1/0/14 | 1.00a |  | 0/0/4 | 1/0/22 | 1.00a |
| **pStage**  I/II/III/IV/unknown |  | 8/1/3/0/0 | 9/5/0/0/1 | 0.68b |  | 3/0/1/0/0 | 14/6/2/1/1 | 0.50b |
| **CD8/0.25 mm2 (average)** |  | 180.1 | 204.5 | 0.27 |  | 137.3 | 203.5 | <0.01 |

pStage, pathological stage; a*EGFR* or *ALK* vs. wild-type; bpStage I or II vs. III or IV.